4
FDA-approved indications
30,000+
patients treated through January 2024
$509M
annual net revenues (2023)
$223M
annual R&D investments (2023)
4
ongoing phase 3 trials
press releases
December 2, 2024
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
November 27, 2024
Novocure to Participate in Upcoming Investor Conferences
events and presentations
Dec 4, 2024
Evercore ISI HealthCONx Conference
Dec 5, 2024
Piper Sandler Healthcare Conference
view all
latest filings
view all
reports
See our online annual reports and more.
2023
annual materials
2022
annual materials
2021
annual materials
contact us
investorinfo@novocure.com
610-723-7427
sign up for email alerts
To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.
"*" indicates required fields